These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20160745)

  • 21. Evidence-informed evidence-making.
    Chalkidou K; Walley T; Culyer A; Littlejohns P; Hoy A
    J Health Serv Res Policy; 2008 Jul; 13(3):167-73. PubMed ID: 18573766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maximizing the clinical utility of comparative effectiveness research.
    Umscheid CA
    Clin Pharmacol Ther; 2010 Dec; 88(6):876-9. PubMed ID: 20962776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NICE's social value judgements about equity in health and health care.
    Shah KK; Cookson R; Culyer AJ; Littlejohns P
    Health Econ Policy Law; 2013 Apr; 8(2):145-65. PubMed ID: 22717361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NICE methodological guidelines and decision making in the National Health Service in England and Wales.
    Gafni A; Birch S; ;
    Pharmacoeconomics; 2003; 21(3):149-57. PubMed ID: 12558466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interview: Setting up NICE International.
    Chalkidou K
    J Comp Eff Res; 2012 Mar; 1(2):121-4. PubMed ID: 24237371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breaking up is hard to do: why disinvestment in medical technology is harder than investment.
    Haas M; Hall J; Viney R; Gallego G
    Aust Health Rev; 2012 May; 36(2):148-52. PubMed ID: 22624634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Public Reasoning and Health-Care Priority Setting: The Case of NICE.
    Rumbold B; Weale A; Rid A; Wilson J; Littlejohns P
    Kennedy Inst Ethics J; 2017; 27(1):107-134. PubMed ID: 28366905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness research in the United States: a progress report.
    Sullivan SD; Carlson JJ; Hansen RN
    J Med Econ; 2013; 16(2):295-7. PubMed ID: 23227997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
    Charlton V
    J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should "standard gamble" and "'time trade off" utility measurement be used more in mental health research?
    Flood C
    J Ment Health Policy Econ; 2010 Jun; 13(2):65-72. PubMed ID: 20919593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence.
    Chalkidou K
    Issue Brief (Commonw Fund); 2009 Jul; 59():1-12. PubMed ID: 19639713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PROMISE AND PLAUSIBILITY: HEALTH TECHNOLOGY ADOPTION DECISIONS WITH LIMITED EVIDENCE.
    Campbell B; Knox P
    Int J Technol Assess Health Care; 2016 Jan; 32(3):122-5. PubMed ID: 27530151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests.
    O'Mahony JF; Paulden M; McCabe C
    Pharmacoeconomics; 2021 Feb; 39(2):139-146. PubMed ID: 33462758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perspectives on the National Institute for Health and Clinical Excellence's recommendations to use health technologies only in research.
    Dhalla IA; Garner S; Chalkidou K; Littlejohns P
    Int J Technol Assess Health Care; 2009 Jul; 25(3):272-80. PubMed ID: 19619345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?
    Eichler HG; Kong SX; Gerth WC; Mavros P; Jönsson B
    Value Health; 2004; 7(5):518-28. PubMed ID: 15367247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can the pharmaceutical industry embrace comparative effectiveness research? A view from inside.
    Berger ML
    Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):565-8. PubMed ID: 24090045
    [No Abstract]   [Full Text] [Related]  

  • 39. Macro trends in pharmaceutical innovation.
    Cohen FJ
    Nat Rev Drug Discov; 2005 Jan; 4(1):78-84. PubMed ID: 15688075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prioritizing health technologies in a Primary Care Trust.
    Wilson E; Sussex J; Macleod C; Fordham R
    J Health Serv Res Policy; 2007 Apr; 12(2):80-5. PubMed ID: 17407656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.